MedTrace Logo

Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma

NCT03015727 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2017-01-10

No results posted yet for this study

Summary

In this study, the investigators aim to compare the progression-free survival (PFS) and side effects of radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients with a satisfactory tumor response (complete response or partial response) after neoadjuvant chemotherapy (NACT).

Conditions

  • Locally Advanced Nasopharyngeal Carcinoma

Interventions

DRUG

Docetaxel

3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.

DRUG

Cisplatin

3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.

RADIATION

IMRT/TOMO

intensity modulated radiation therapy or tomotherapy

DRUG

Chemotherapy

2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.

Sponsors & Collaborators

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • The Central Hospital of Lishui City

    collaborator OTHER

  • Jinhua Central Hospital

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Ningbo Medical Center Lihuili Eastern Hospital

    collaborator UNKNOWN

  • People's Hospital of Quzhou

    collaborator OTHER

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Xiaozhong Chen · Zhejiang Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2022-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03015727 on ClinicalTrials.gov